Akeso’s IL-17A MONOCLONAL ANTIBODY (GUMOKIMAB) COMPLETION OF PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS

Akeso's Il 17a Monoclonal Antibody (gumokimab) Completion Of Patient Enrollment In Phase Ii Clinical Trial For The Treatment Of Ankylosing Spondylitis

Facebook Comments

Leave a Reply

CommentLuv badge